ClinicalTrials.gg
CompletedNCT06547359Updated Nov 14, 2024

A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects

A Phase 1 interventional study of Obicetrapib 10mg and Ezetimibe 10mg in Healthy Volunteers, sponsored by NewAmsterdam Pharma. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by NewAmsterdam Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
94
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects

Read the detailed description

A Study to Evaluate the PK of obicetrapib tablets with and without co-administration of daily doses of ezetimibe tablets and the PK of ezetimibe tablets with and without co-administration of daily doses of obicetrapib tablets.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, non-smoking, male and female subjects, from 18 to 65 years of age.
  • ≥18.5 and ≥30 kg/m2
  • Females may be of childbearing or non-. Childbearing potential (physically capable of becoming pregnant). Non-childbearing potential: Surgically sterile (i.e., both ovaries removed, uterus removed, or bilateral tubal ligation); and/or (no menstrual period for at least 12 consecutive months without any other medical cause and FSH and LH values consistent with being postmenopausal).
  • Willing to use acceptable, effective methods of .
  • Able to tolerate venipuncture.
  • Be informed of the nature of the study and give written consent prior to any study procedure.

Exclusion criteria

Exclusion Criteria:

  • History of neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  • Known or suspected carcinoma.
  • History of or idiosyncratic reaction to obicetrapib, ezetimibe, or any other drug substances with similar activity.
  • History of clinically significant angioedema.
  • History of myopathy, rhabdomyolysis, or myalgia, which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  • History of pancreatitis, which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  • History of severe cutaneous adverse reactions (SCARs), Steven-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reaction with eosinophilic and systemic symptoms (DRESS), which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  • Presence of hepatic or renal dysfunction.
  • History of malabsorption within the last year or presence of clinically significant gastrointestinal (GI) disease.
  • Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
  • History of drug or alcohol addiction requiring treatment.
  • Positive test result for , surface antigen, or antibody.
  • Positive test result for urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and tricyclic antidepressants) or urine cotinine.
  • Difficulty fasting or consuming standard meals.
  • Use of tobacco or nicotine-containing products within six (6) months prior to the first drug administration.
  • Females who:

    • Have used implanted, injected, intravaginal, or intrauterine hormonal within six (6) months prior to the first drug administration;
    • Have used oral or transdermal hormonal contraceptives within 21 days prior to the first drug administration;
    • Are pregnant (serum β-hCG consistent with pregnancy); or
    • Are breast-feeding.
  • Donation or loss of whole blood (including clinical trials):

    • ≥50 mL and \<500 mL within 30 days prior to the first drug administration; or
    • ≥500 mL within 56 days prior to the first drug administration.
  • Participation in a clinical trial that involved administration of an medicinal product within 30 days prior to the first drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results.
  • On a special diet within 30 days prior to the first drug administration (e.g., liquid, protein, raw food diet).
  • Have had a tattoo or body piercing within 30 days prior to the first drug administration.
  • Have clinically significant findings in vital signs measurements.
  • Have clinically significant findings in a 12-lead .
  • Have clinically significant abnormal laboratory values.
  • Have significant diseases.
  • Use of any of the following within 30 days prior to drug administration:

    • Bile acid sequestrant (e.g., cholestyramine)
    • Cyclosporine
    • Digoxin
    • Drugs that alter GI pH/movement (e.g., omeprazole, ranitidine)
    • Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism
    • Fibrates (e.g., fenofibrate)
    • Gemfibrozil
    • Glipizide
    • Inducers and inhibitors of breast cancer resistant protein
    • Inducers and inhibitors of
    • Inducers and inhibitors of OATP1B1/OATP1B3
    • Inducers and inhibitors of P-glycoprotein
    • Statin
    • Warfarin
  • Have clinically significant findings from a physical examination.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Active comparator
    obicetrapib with and without co-administration of ezetimibe

    Ezetimibe 10mg tablets daily from Days 1-17 plus obicetrapib 10mg tablets on Day -9 and Day 8

    Drug: Obicetrapib 10mg · Drug: Ezetimibe 10mg

  • Active comparator
    ezetimibe with and without co-administration of obicetrapib

    Obicetrapib 10mg tablets daily from Days 1-15 plus ezetimibe10mg tablets on Day -3 and Day 12

    Drug: Obicetrapib 10mg · Drug: Ezetimibe 10mg

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)

    Maximum measured analyte concentration

    Time frame: time zero (0) to the time of the last measurable analyte concentration (t), up to 18 days

  2. AUCt (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)

    The area under the analyte concentration versus time curve

    Time frame: time zero (0) to the time of the last measurable analyte concentration (t)

  3. AUCinf (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)

    The area under the analyte concentration versus time curve

    Time frame: m time zero to infinity

Secondary outcomes

  1. Tmax (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)

    Time of the maximum measured analyte concentration

    Time frame: zero (0) to the time of the last measurable analyte concentration (t), up to 18 days

  2. Kel (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)

    The apparent first-order elimination rate constant

    Time frame: time zero (0) to the time of the last measurable analyte concentration (t), up to 18 days

  3. Thalf (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)

    The apparent elimination half-life

    Time frame: zero (0) to the time of the last measurable analyte concentration (t), up to 18 days

  4. CL/F (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)

    Total body clearance

    Time frame: time zero (0) to the time of the last measurable analyte concentration (t), up to 18 days

  5. Vd/F (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)

    Apparent volume of distribution

    Time frame: time zero (0) to the time of the last measurable analyte concentration (t), up to 18 days

07

Study locations

1 site
  • PharmaMedica Research Inc.
    Toronto, Ontario M1S 3V6, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Nov 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Aug 9, 2024
StartActual
Oct 1, 2024
Primary completionActual
Nov 12, 2024
CompletionActual
Nov 12, 2024
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06547359
Lead sponsor
NewAmsterdam Pharma
Collaborators
Pharma Medica Research, Inc.
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Oct 1, 2024
Primary completion
Nov 12, 2024
Completion
Nov 12, 2024
Last update
Nov 14, 2024

Study contacts

Mark M Feldman
principal investigator · Pharma Medica Research, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: TA-8995 · Ezetimibe

Start the discussion